Verastem (VSTM) Competitors $4.96 +0.08 (+1.53%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. GERN, RGLS, MYGN, ZBIO, EBS, RIGL, LXRX, XOMA, CBIO, and VNDAShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Verastem vs. Its Competitors Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma Emergent Biosolutions Rigel Pharmaceuticals Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Verastem (NASDAQ:VSTM) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability. Is VSTM or GERN more profitable? Verastem has a net margin of 0.00% compared to Geron's net margin of -119.54%. Geron's return on equity of -47.86% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -2,003.62% -127.97% Geron -119.54%-47.86%-26.78% Do analysts prefer VSTM or GERN? Verastem presently has a consensus price target of $13.38, indicating a potential upside of 169.39%. Geron has a consensus price target of $4.61, indicating a potential upside of 256.07%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more volatility & risk, VSTM or GERN? Verastem has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Do institutionals & insiders have more ownership in VSTM or GERN? 88.4% of Verastem shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 2.1% of Verastem shares are owned by company insiders. Comparatively, 7.4% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to VSTM or GERN? In the previous week, Geron had 2 more articles in the media than Verastem. MarketBeat recorded 10 mentions for Geron and 8 mentions for Verastem. Geron's average media sentiment score of 0.81 beat Verastem's score of -0.23 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Geron 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, VSTM or GERN? Verastem has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$10K27,282.68-$130.64M-$3.20-1.55Geron$76.99M10.71-$174.57M-$0.21-6.17 SummaryGeron beats Verastem on 9 of the 17 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.50M$2.92B$5.56B$9.26BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.5520.2728.5819.56Price / Sales27,282.68298.79434.47183.65Price / CashN/A43.1536.0257.93Price / Book-7.647.668.165.58Net Income-$130.64M-$55.11M$3.24B$257.82M7 Day Performance3.22%0.03%-0.64%-0.39%1 Month Performance-11.97%7.47%4.93%7.80%1 Year Performance34.92%-3.28%26.04%12.95% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem3.0776 of 5 stars$4.97+1.5%$13.38+169.4%+45.1%$272.50M$10K-1.5550GERNGeron3.4153 of 5 stars$1.37-4.2%$5.06+269.5%-74.3%$872.58M$76.99M-6.5270News CoverageRGLSRegulus Therapeutics1.6356 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830MYGNMyriad Genetics4.5791 of 5 stars$5.29-5.5%$14.38+171.9%-81.2%$487.63M$837.60M-4.722,700News CoveragePositive NewsZBIOZenas BioPharma1.5644 of 5 stars$9.79-2.4%$36.67+274.5%N/A$409.52M$5M-2.76N/AEBSEmergent Biosolutions4.1221 of 5 stars$6.63-5.2%$14.33+116.2%-38.7%$359.88M$1.04B-2.452,420RIGLRigel Pharmaceuticals3.0643 of 5 stars$18.84-0.5%$36.40+93.2%+78.5%$336.67M$179.28M9.10160Positive NewsLXRXLexicon Pharmaceuticals2.5514 of 5 stars$0.87-3.1%$3.67+320.1%-45.8%$315.51M$31.08M-1.71140XOMAXOMA Royalty3.8776 of 5 stars$26.17-2.9%$69.50+165.6%-2.6%$313.26M$28.49M-22.7610CBIOCrescent Biopharma3.1397 of 5 stars$15.29-3.8%$25.00+63.5%N/A$298.92M$10K-0.3350News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeVNDAVanda Pharmaceuticals4.6957 of 5 stars$4.89-1.6%$16.50+237.4%-20.9%$288.17M$198.77M-6.52290 Related Companies and Tools Related Companies Geron Alternatives Regulus Therapeutics Alternatives Myriad Genetics Alternatives Zenas BioPharma Alternatives Emergent Biosolutions Alternatives Rigel Pharmaceuticals Alternatives Lexicon Pharmaceuticals Alternatives XOMA Royalty Alternatives Crescent Biopharma Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VSTM Stock Alerts